CYTOKINETICS, INCORPORATED Deferred Tax Liabilities, Gross
CYTOKINETICS, INCORPORATED (CYTK) had Deferred Tax Liabilities, Gross of $20.84 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $20.84M.
- 2024-12-31: Deferred Tax Liabilities, Gross $22.04M.
- 2023-12-31: Deferred Tax Liabilities, Gross $24.24M.
- 2022-12-31: Deferred Tax Liabilities, Gross $26.10M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $20.84M 10-K · filed 2026-02-26 |
| 2024-12-31 | $22.04M 10-K · filed 2026-02-26 |
| 2023-12-31 | $24.24M 10-K · filed 2025-02-27 |
| 2022-12-31 | $26.10M 10-K · filed 2024-02-28 |
| 2021-12-31 | $31.60M 10-K · filed 2023-03-01 |
| 2020-12-31 | $11.41M 10-K · filed 2022-02-25 |
| 2019-12-31 | $15.54M 10-K · filed 2021-02-26 |
| 2018-12-31 | $2.70M 10-K · filed 2020-03-04 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |